Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

SAN ANTONIO, and SAN FRANCISCO, Dec. 12, 2010 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at SABCS evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-seven percent (61/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and anywhere from 30% to 80% develop metastatic disease.(1)  

A total of 66 of the 70 patients treated in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR),  including confirmed complete and partial responses per RECIST.  As of October 26, 2010, confirmed ORR for all evaluable patients was 32% (10/31) for the q14d schedule and 26% (9/35) for the q21d schedule, including two confirmed complete responses (CRs) on the q14d schedule.  An additional four patients had near CRs, with 100% disappearance of all target lesions.  The combined ORR for all evaluable patients was 29% (19/66).  Clinical benefit rate for the 66 evaluable patients was 41% (defined as CR+PR+SD greater than or equal to 6 mos).

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and MUNICH , May 22, 2013 /PRNewswire/ ... marketer of transcatheter aortic valve implantation (TAVI) systems for the ... results of the J enaValve Eval U ation of ... Pa T ients with S E vere Ao R tic ... . JUPITER is a post-market registry to evaluate five-year long ...
(Date:5/22/2013)... , May 22, 2013  The Lupus Research Institute ... to advancing new treatments for lupus nephritis, a serious ... of patients. The conference launched a new international alliance ... Nephritis Trials Network (LNTN). More than 50 ... kidney came together to focus on two critical questions: ...
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... More Targeted Asthma Control, MENLO PARK, Calif., ... today that it has begun shipments of its,Insight(TM) ... 2008, the Insight eNO,System combines the accuracy, speed, ... office-based measurements of exhaled,nitric oxide (eNO). Exhaled nitric ...
... Team, WEST BEND, Wis., April 30 Mach ... products,for animal health, announced today the appointment of Dr. ... his new role, Dr. Nash will be responsible for ... use in,the dairy, beef, poultry, and swine markets., ...
Cached Medicine Technology:Apieron, Inc. Begins Customer Shipments of the Insight(TM) eNO System 2Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist 2
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 Jury ... nation’s first trial involving a da Vinci lawsuit, ... case, the family of a man who allegedly died of ... more than $8 million in damages from Intuitive Surgical, Inc. ... its physician training program for the da Vinci Surgical System ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...
(Date:5/22/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution plans and health reimbursement ... in 2014 as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:5/22/2013)... may be reaping enormous income for patients whose ... contracted in their intensive care units. , In ... American Journal of Medical Quality , the ... an avoidable central line-associated bloodstream infection (CLABSI) costs ... a similar infection-free patient. Moreover, hospitals earn nearly ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4
... Daniel D. Von Hoff, Physician-in-Chief for the Translational Genomics Research ... Society of Clinical Oncology (ASCO) for his cancer research. ... A. Karnofsky Memorial Award and Lecture at ASCO,s 46th Annual ... ASCO will present the award to Dr. Von Hoff "for ...
... B for those with scent-robbing viral infection, study found ... help people who lose their sense of smell after ... study, 15 patients with post-viral olfactory dysfunction (PVOD) had ... patients were compared with PVOD patients treated with vitamin ...
... can be lost, treatment can work again , THURSDAY, April ... which certain tumor cells that become resistant to cancer drugs ... lead to new ways to combat drug resistance in cancer ... April 1 in the journal Cell . , Although ...
... medicine specialists), subspecialists, medical students, and allied health ... Medicine 2010, the annual scientific meeting of the ... 24 (Thursday - Saturday), at the Toronto Convention ... devoted to adult medicine and is the second-largest ...
... promise for safely removing large brain tumors from an ... sinus cavities, clinical researchers at the Brain Tumor Center ... University Hospital have found. The findings, to be ... Journal of Neurosurgery and previously published online in ...
... of elderly patients. In many cases, a hip fracture is ... health, setting off a long list of potential complications. ... issue of The Journal of Bone and Joint Surgery ... by the American Society of Anesthesiologists (ASA)-is a leading indicator ...
Cached Medicine News:Health News:TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award 2Health News:Study Suggests How Some Cancers Resist Treatment 2Health News:Study Suggests How Some Cancers Resist Treatment 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 2Health News:All you need to know about adult medicine is at Internal Medicine 2010 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 4Health News:All you need to know about adult medicine is at Internal Medicine 2010 5Health News:All you need to know about adult medicine is at Internal Medicine 2010 6Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 2Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 3Health News:Hip surgery success partially predicted by number of other existing conditions 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: